Dexcom launches generative AI platform for Stelo users

Dexcom on Tuesday announced a man-made intelligence feature for its Stelo continuous glucose monitor that provides users a customized look into how meals, sleep and activity impact their glucose levels. It’s the primary iteration of a latest generative AI platform that the corporate has been constructing with Google Cloud. 

Stelo is an over-the-counter CGM that pokes through the skin to measure real-time blood sugar levels. The sensor launched in August and could be utilized by any adult who doesn’t take insulin. 

The report reflects Dexcom’s effort to make Stelo more personalized and fascinating for consumers as it really works to penetrate a latest market. 

“The No. 1 feedback we get is users wish to see more,” Jake Leach, chief operating officer at Dexcom, told CNBC in an interview. “They’re investing and wearing the product, and so they wish to have the opportunity to take probably the most advantage of all the information that they are generating.”

Dexcom is using Google’s Gemini models and its Vertex AI platform as the inspiration for its latest AI offering. Vertex AI allows developers to construct applications that synthesize various kinds of data, which could be notoriously difficult in health care. 

Leach said Dexcom can also be exploring how its generative AI platform could be used across its other CGM products, but the corporate is proceeding extra fastidiously since patients depend on them to forestall medical emergencies. 

“It really felt like Stelo was the correct place to do that for the primary time,” he said.

An existing insights report has already been available to users inside the Stelo app, nevertheless it followed a more standard template format each week. Dexcom believes the AI-generated report will likely be more worthwhile to users because it’s personalized, Leach said. 

If there’s per week where a user will not be moving enough after meals, as an illustration, the report would come with relevant suggestions and academic materials to assist. 

Stelo’s AI reports don’t give users medical advice, though Dexcom has been using an AI framework from the U.S. Food and Drug Administration to assist guide the feature’s development, Leach said. The FDA approved Stelo in March. 

Eventually, Dexcom wants to make use of its generative AI platform to deliver real-time feedback to users as a substitute of just weekly reports. The corporate can also be exploring how the technology could act as a predictive indicator for potential problems, very like a check engine light on a automobile. 

“It gives you a way for what may very well be happening, and proposals of where it is advisable to go to hunt more advice,” Chris Sakalosky, vice chairman of strategic industries for Google Cloud, told CNBC in an interview.   

Dexcom’s updated weekly report began rolling out to Stelo users this week.